Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Sales (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Return on Sales data on record, last reported at 0.8% in Q3 2025.

  • For Q3 2025, Return on Sales rose 165.0% year-over-year to 0.8%; the TTM value through Sep 2025 reached 0.8%, up 278.0%, while the annual FY2024 figure was 3.83%, 95.0% down from the prior year.
  • Return on Sales reached 0.8% in Q3 2025 per FHTX's latest filing, up from 1.6% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.8% in Q3 2025 and bottomed at 652.68% in Q3 2021.
  • Average Return on Sales over 5 years is 48.56%, with a median of 5.27% recorded in 2023.
  • Peak YoY movement for Return on Sales: plummeted -54826bps in 2021, then soared 64880bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 39.98% in 2021, then skyrocketed by 83bps to 6.9% in 2022, then soared by 39bps to 4.18% in 2023, then tumbled by -63bps to 6.83% in 2024, then surged by 88bps to 0.8% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.8% in Q3 2025, 1.6% in Q2 2025, and 2.62% in Q1 2025.